MCOLN1 and lymphoma: Higher doses of temsirolimus have only been used as a last resort in clinical trials against aggressive forms of lymphoma with WBC values reaching 500–600 nM (Hudes et al., 2007), which is still more than 25 times lower than the rapamycin concentration required to half‐maximally activate TRPML1 (Zhang et al., 2019).